Noradrenergic neurons in the locus ceruleus contain neuropeptide Y and galanin, which project to the hypothalamic region. We have investigated the regulatory mechanisms of these peptides on norepinephrine release in rat hypothalamic slices in vitro. Neuropeptide Y and galanin significantly inhibited the stimulation-evoked [ Noradrenergic neurons containing NPY and Gal in the locus ceruleus preferentially project to the hypothalamus and form a dense fiber network in this region. 1 However, the functional significance of the neurons that contain classical transmitters and the peptides is not fully elucidated. In the periphery, nerve stimulation of the pig spleen causes a corelease of NE and NPY, 5 but in the rat portal vein, NPY inhibits NE release both in normotensive and hypertensive rats.
N europeptide Y (NPY), a 36-amino acid peptide, and galanin (Gal), a 29-amino acid peptide, have a wide and specific distribution both in the central and peripheral nervous system. 1 -4 These peptides are colocalized with classical neurotransmitters like norepinephrine (NE) and epinephrine in specific neuronal systems. 1 -4 Noradrenergic neurons containing NPY and Gal in the locus ceruleus preferentially project to the hypothalamus and form a dense fiber network in this region. 1 However, the functional significance of the neurons that contain classical transmitters and the peptides is not fully elucidated. In the periphery, nerve stimulation of the pig spleen causes a corelease of NE and NPY, 5 but in the rat portal vein, NPY inhibits NE release both in normotensive and hypertensive rats. 6 It has been postulated that NPY interacts with « 2 -adrenergic receptors because this peptide increases the number of a 2 -adrenergic binding sites 7 or enhances the inhibitory effects of clonidine on potassium-induced NE release in rat medulla oblongata. 8 Recent studies have shown that pertussis toxin, islet activating protein (LAP), inactivates the inhibitory guanine nucleotide-sensitive binding protein (inhibitory guanosine triphosphate [GTP]-binding protein, Ni). 9 -14 The inactivation impairs the a 2 -adrenergic receptor-mediated regulation of adenylate cyclase as well as cellular responses caused by activation of the receptors. 9 -10 ' 14 In this presentation, we have described the effects of NPY and Gal on the electrically evoked release of [ 3 H]NE from rat hypothalamic slices. We have also examined the effects of an a 2 -adrenergic receptor agonist and antagonist, as well as the effects of inactivation of the coupling protein (Nj) by IAP on the modulation of NE release.
Materials and Methods
Male Sprague-Dawley rats (150-200 g) were used for the experiments. All rats were maintained and housed in a temperature-and humidity-controlled room. The rats were fed regular pellet food and tap water ad libitum at least 1 week before the experiment. The rats were killed by decapitation, and the whole hypothalamus was rapidly dissected on ice by means of the method of Glowinski and Iversen. 25 .0, glucose 11.1, ascorbic acid 0.11, and disodium EDTA 0.04 saturated with a 95% O 2 and 5% CO 2 mixture at 37° C, pH 7.4. The slices were incubated with 3 ml fresh buffer containing 0.1 fiM [ 3 H]NE (specific activity 40.8 Ci/mmol; New England Nuclear Research Products, Boston, Massachusetts) for 20 minutes at 37° C. After the slices (5-7 mg) were rinsed with fresh buffer, they were transferred to a superfusion chamber (200 fi\), jacketed with 37° C water, and suspended between two platinum electrodes (25 mm apart, 2.0 mm long). Slices were superfused at a rate of 0.7 ml/min with Krebs-Ringer bicarbonate buffer. Sample collection began after 60 minutes of superfusion when basal outflow of tritium had stabilized to a constant level. Samples of superfusate were collected at 7-minute intervals until the end of the experiment (at 130 minutes). The first period of electrical stimulation (SI) was applied at 67 minutes, and the second period of electrical stimulation (S2) was applied at 116 minutes after the beginning of superfusion. Electrical stimulation was delivered by a Grass stimulator (model S4K, Quincy, Massachusetts) and consisted of trains of unipolar, rectangular pulses (1 Hz, 20 mA, 2 msec for 2 minutes). At the end of the experiment, the slices were sonicated for 20 seconds. Radioactivity in collected samples and tissue slices was determined by liquid scintillation counting (Tri-curb Liquid Scintillation Spectrometer 3255, Packard Instr. Co., Inc., Sterling, Virginia).
The amount of radioactivity in each sample was calculated by dividing the total tritium collected in each sample by the total tritium present in the tissue at the time of the sample collection (percent fractional release). Basal outflow during the two prestimulation periods (bl and b2, respectively) was calculated from the tritium collected in the two 7-minute samples just before SI and S2. The stimulation-evoked release was calculated by subtracting the basal outflow during the 7-minute prestimulation period from the values in samples collected during 2 minutes and after 5 minutes of electrical stimulation.
In control experiments, SI and S2 were carried out in the absence of any added drugs. The effects of 5 -bromo-6 -(2 -imidazolin-2 -ylamino)-quinoxaline (UK 14,304), NPY, or Gal were evaluated only in S2, with SI serving as an internal control. Superfusion with UK 14,304, NPY, or Gal was initiated 14 minutes before S2 and maintained until the end of the experiment. The effects of UK 14,304, NPY, or Gal on the stimulation-evoked [ 3 H]NE release were determined by comparison of the S2/S1 ratios obtained in control slices with the values in slices treated with the tested drug in S2. To examine the effect of blockade of a 2 -adrenergic receptors, 2-[2-(l,4-benzodiozanyl)]-2-imidazolin HC1 (RX 781094) was added to the superfusion medium 28 minutes before SI and maintained until the end of the experiment.
To inactivate the N,, the slices were incubated for 1 hour at 37° C in an atmosphere of 95% O 2 and 5% CO 2 in a mixture of 920 /il Krebs-Ringer bicarbonate buffer and 80 ^10.01 M sodium phosphate buffer that contained 0.05 M NaCl and 2 or 8 /xg IAP. For control experiments, the slices were incubated in the same buffer mixture without IAP. Subsequently the slices were washed three times with fresh buffer and incubated in the presence of 0. 
Statistics
Data are presented as mean±SEM. Differences between the means of the drug treatment and their corresponding controls were tested with one-way analysis of variance. To compare the means of the different study groups, statistical analyses were performed with the Wilcoxon rank-sum test. Ap value less than 0.05 was accepted as the level of significance.
Results

Effects of Neuropeptide Y and Galanin Alone and in Combination With UK 14,304 or RX 781094 on the Stimulation-Evoked Release of [ 3 HjNorepinephrine
The results presented in Table 1 Values are represented as mean±SEM. Slices were stimulated twice (SI and S2) at 1 Hz (20 mA, unipolar rectangular pulses of 2-msec duration for 2 minutes). Neuropeptide Y (NPY), galanin (Gal), and UK 14,304 (UK) were added 14 minutes before S2. Fractional release at SI and S2 was calculated by subtracting basal outflow from total outflow of tritium during stimulation period (2-minute stimulation and after 5 minutes) and is expressed as percentage of the tritium content of the tissue at the onset of stimulation.
• Table 1 show that inhibitory potency of NPY or Gal was significantly attenuated in the presence of the a 2 -adrenergic receptor antagonist but not completely abolished.
Effects of Pretreatment of Slices With Islet Activating Protein on the Inhibition of l 3 H]Norepinephrine Release by UK 14,304 or by the Neuropeptides
Pretreatment of the hypothalamic slices with LAP (8 /Ag/ml) did not significantly alter the stimulationevoked fractional release of [ 17 However, functional role of these peptides in adrenergic neurotransmission in the central nervous system is still not well understood. We have therefore investigated the effects of NPY and Gal on [ 3 H]NE release and their regulatory mechanisms in the rat hypothalamus, a region in which NE and NPY or Gal coexistent neurons are present. 1 The results of the present study show that NPY and Gal inhibit stimulation-evoked [ 3 H]NE release in the hypothalamus in a dose-dependent manner. In this study, we have used a concentration range of 10-9 -l0" 7 M for NPY and lO^-lO" 6 M for Gal. These concentrations are higher than those expected by endogenous NPY and Gal contents in the hypothalamus.
3 ' 18 However, higher dosages were necessary because the neuropeptides might poorly penetrate into the hypothalamic slices and could be gradually inactivated by degradation in the in vitro study.
On the other hand, the a 2 -adrenergic receptor agonist UK 14,304 also inhibits the stimulationevoked Recently, it has been shown that activation of a 2 -adrenergic receptors is followed by inhibition of adenylate cyclase and a concomitant reduction of cyclic adenosine monophosphate (AMP) concentration in the cells. 9 -11 LAP inactivates the inhibitory GTP-binding protein (N,) by adenosine diphosphate ribosylation and has been widely used to determine the involvement of the N, unit in the receptormediated inhibition of adenylate cyclase or in the overall cellular responses elicited by activation of the receptors. Boyer et al 19 20 and that a significant number of NPY-binding sites in the rat cerebral cortex are guanine nucleotide-sensitive. 21 Furthermore, Kassis et al 22 have reported the inhibition of NPY of isoproterenol-stimulated cyclic AMP accumulation in primary rat atrial cells and its reversal by LAP pretreatment. In this study, we did not measure the cyclic AMP level because whole slice cyclic AMP levels may not accurately reflect cyclic AMP content inside the noradrenergic axon terminals. 23 Further studies are required to determine whether NPY and Gal may interact with only a 2 -adrenergic receptor-mediated GTP-binding protein or with other coupling proteins.
Some evidence has been presented that NE release from the hypothalamic region is altered in hypertensive rat models compared with normotensive rats. Meldrum and Westfall 24 and Qualy and Westfall 25 have demonstrated that NE release from anterior hypothalamus was lower in spontaneously hypertensive rats than in Wistar-Kyoto rats, but the release from posterior and paraventricular nuclei of the hypothalamus was greater in spontaneously hypertensive rats than in Wistar-Kyoto rats. Furthermore, Martin et al 26 have observed that microinjection of NPY into the posterior hypothalamus evoked a concentration-dependent increase in mean arterial blood pressure in anesthetized rats. On the contrary, a hypotensive action of NPY has been observed after intracisternal administration. 27 It has been shown that intracisternally injected Gal lowered blood pressure in anesthetized rats. 28 These previous observations, coupled with our present result that NPY and Gal inhibit NE release in the hypothalamus, would suggest that NPY and Gal may play an important role in central regulation of blood pressure although the relation between these peptides and blood pressure control has to be further elucidated.
In summary, the present study demonstrates that NPY and Gal inhibit NE release in rat hypothalamic slices. A part of the mechanisms could be explained by the interactions with presynaptic a 2 -adrenergic receptors and inhibitory GTP-binding proteins. The inhibitory modulation of central neurotransmitter release by NPY and Gal indicates the possible involvement of these peptides in regulating blood pressure in the central nervous system.
